Ligand Pharmaceuticals
LGND
$70.02
Share price
-0.78%
Change (1 day)
-8.29%
Change (1 year)
Ligand Pharmaceuticals (LGND) - Total liabilities
Total liabilities on the balance sheet as of December 2023 : $86.3 M
According to Ligand Pharmaceuticals's latest financial reports the company's total liabilities are $86.3 M. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Ligand Pharmaceuticals - Total liabilities on balance sheet (from 2001 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $86.3 M | -47.75% |
| 2022-12-31 | $0.16 B | -65.33% |
| 2021-12-31 | $0.47 B | -27.01% |
| 2020-12-31 | $0.65 B | -10.3% |
| 2019-12-31 | $0.72 B | 3.97% |
| 2018-12-31 | $0.69 B | 177.32% |
| 2017-12-31 | $0.25 B | 9.38% |
| 2016-12-31 | $0.23 B | 2.03% |
| 2015-12-31 | $0.22 B | -3.2% |
| 2014-12-31 | $0.23 B | 323.99% |
| 2013-12-31 | $55.1 M | -29.15% |
| 2012-12-31 | $77.77 M | -30.8% |
| 2011-12-31 | $0.11 B | 39.78% |
| 2010-12-31 | $80.4 M | -41.76% |
| 2009-12-31 | $0.13 B | -24.06% |
| 2008-12-31 | $0.18 B | 26.12% |
| 2007-12-31 | $0.14 B | -51.74% |
| 2006-12-31 | $0.29 B | -29.72% |
| 2005-12-31 | $0.42 B | 4.23% |
| 2004-12-31 | $0.40 B | 15.98% |
| 2003-12-31 | $0.35 B | 74.57% |
| 2002-12-31 | $0.20 B | 14.87% |
| 2001-12-31 | $0.17 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $98.78 B | 114,361.84% | 🇺🇸 USA |
 Pfizer PFE | $137.21 B | 158,889.84% | 🇺🇸 USA |
 Eli Lilly LLY | $53.14 B | 61,476.77% | 🇺🇸 USA |
 Amgen AMGN | $90.92 B | 105,252.07% | 🇺🇸 USA |
 Baxter BAX | $19.80 B | 22,851.69% | 🇺🇸 USA |
 Merck MRK | $69.04 B | 79,897.22% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $82.48 B | 95,473.73% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $58.82 B | 68,061.36% | 🇬🇧 UK |
 Spectrum Pharmaceuticals
SPPI | $80.87 M | -6.30% | 🇺🇸 USA |